EUDA Health Holdings Limited runs a Singapore property management franchise alongside a Malaysian wellness distribution business it acquired from a related party in a share-only deal. The company has spent three years pivoting from a closed medical clinic network into wellness therapies, stem cell distribution, and a nonbinding cell therapy memorandum, while carrying a going concern opinion and a Nasdaq delisting clock that runs out in October 2026.
The tension is that the stock prices in a biotech option the filings do not back with any near-term cash flow path. Revenue reached $6.8 million in 2025, yet the company lost money all year. Cash on hand sat under $400,000 against a working capital deficit of $4.8 million. The thesis rests on four variables: Nasdaq compliance, the July 2026 cell therapy memorandum, CK Health wellness revenue, and the ability to fund operations without delisting.